CGT Catapult names new CEO

Mathew Durdy

Mathew Durdy has been appointed as CEO to lead the Cell and Gene Therapy Catapult as the organisation prepares to accelerate innovation, growth and productivity in the UK.

Durdy, who currently serves as the organisation’s Chief Business Officer, was part of the 2012 team that created the CGT Catapult. He replaces founder CEO Keith Thompson who is retiring in the spring.

“There is so much that we can do that will accelerate the growth of this industry which creates high value jobs in the UK, and at the same time brings life changing treatments to children, cancer sufferers, and many others with currently unmet acute and chronic healthcare needs,” he said.